Michael B. Major

This study identifies TMEM106B as an alternative receptor for SARS-CoV-2 S-E484D variant entry, independent of ACE2, in airway-derived cell models.

Pioneer and Altimeter provide fast, accurate analysis of DIA proteomics data, improving peptide coverage and speed compared to existing tools.

This study identifies MAFG as a driver of melanoma progression by interacting with MITF to alter gene expression and promote a dedifferentiated melanoma phenotype.

The paper introduces optogenetic proximity labeling to map mitochondrial surface proteomes and ribosome pools, revealing Miro1's role in spatially organizing mitochondrial protein biogenesis.

This paper introduces VVD-065, a covalent NRF2 inhibitor that enhances NRF2 degradation and sensitizes tumors to therapy, supporting a Phase I clinical trial.

The paper maps the hSOX10 protein interactome in human melanoma using miniTurbo biotinylation and mass spectrometry, identifying 847 candidate interactors and highlighting key functional pathways.

The paper identifies de novo mutations contributing to meningomyelocele risk by analyzing trios and finding damaging mutations in 22.3% of cases.

This paper identifies Pyrimethamine and its derivative WCDD115 as potent inhibitors of NRF2 by targeting DHFR and one-carbon metabolism, with WCDD115 showing 22-fold greater efficacy.

The paper uses proximity proteomics to identify proteins interacting with Afadin in MDCK cells, revealing new adherens junction components and their overlap with other junctions.